Eureka Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2006-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
T-Cell Therapy (ECT204) in Adults With Advanced HCC
- Conditions
- Hepatocellular CarcinomaLiver Cancer, AdultLiver NeoplasmMetastatic Liver Cancer
- Interventions
- First Posted Date
- 2021-04-28
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Eureka Therapeutics Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT04864054
- Locations
- 🇺🇸
Fred Hutchinson Cancer Center, University of Washington, Seattle, Washington, United States
🇺🇸City of Hope, Duarte, California, United States
🇺🇸Kansas University Medical Center, Principal Investigator:, Westwood, Kansas, United States
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
- Conditions
- HepatoblastomaLiver NeoplasmsMetastatic Liver CancerHepatocellular Carcinoma (HCC)Liver CancerHEMNOS
- Interventions
- First Posted Date
- 2020-11-18
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Eureka Therapeutics Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT04634357
- Locations
- 🇺🇸
UCSF Benioff Children's Hospitals, San Francisco, California, United States
🇺🇸Dana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts, United States
Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)
- Conditions
- Liver CancerHepatocellular CarcinomaLiver NeoplasmMetastatic Liver Cancer
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Eureka Therapeutics Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04502082
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸Kansas University Medical Center, Westwood, Kansas, United States
Study of ET140202 T Cells in Adults With Advanced Hepatocellular Carcinoma
- Conditions
- Metastatic Liver CancerLiver CancerLiver NeoplasmHepatocellular Carcinoma
- First Posted Date
- 2019-06-25
- Last Posted Date
- 2022-08-23
- Lead Sponsor
- Eureka Therapeutics Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT03998033
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸UC Irvine, Irvine, California, United States
🇺🇸UC Davis, Sacramento, California, United States
Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma
- Conditions
- Lymphoma, B-Cell
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Eureka Therapeutics Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT03415399
- Locations
- 🇨🇳
Peking University Cancer Hospital, Beijing, China
- Prev
- 1
- 2
- Next